DETERMINATION OF CISPLATIN IN HUMAN BLOOD PLASMA AND URINE USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY FOR ONCOLOGICAL PATIENTS WITH A VARIETY OF FATTY TISSUE MASS FOR PREDICTION OF TOXICITY

Clearance of cisplatin, which was determined by the chromatographic method, is reduced in individuals with increased adipose tissue mass. Research data suggest that overweight affects cisplatin elimination from the body. The greater body fat mass can contribute to a greater rise of triglyceride level in blood serum. Triglycerides in blood plasma may serve as an additional indicator of higher cisplatin toxicity as a cardiotoxicity marker.